Neoadjuvant SNF Precision Therapy Phase III

NCT06913777 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

404

Enrollment

OTHER

Sponsor class

Conditions

Neoadjuvant Therapy

Interventions

DRUG: Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib
DRUG: Chemotherapy (wP-EC)

Sponsor

Fudan University